First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors

Date 26 September 2015
Event European Cancer Congress 2015
Session Early Drug Development I
Topics Clinical Research
Basic Scientific Principles
Presenter Azaro, A.